University of Adelaide Begins Human Trial of Omicron COVID Vaccine Booster Using PharmaJet Needle-free System
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection System (NFIS).
The DNA-vaccine booster is one of the few vaccines worldwide targeting the Omicron variant, rather than the original strain of the virus. As DNA vaccines can be modified easily the vaccine can be quickly adapted to future variants. Lead investigator, Associate Professor Branka Grubor-Bauk, head of Viral Immunology at the University of Adelaide’s Adelaide Medical School commented, “We need to continue developing 'next generation' COVID-19 vaccines because the virus will continue to mutate, particularly in countries with low vaccination rates and high rates of uncontrolled transmission.” The vaccine is being exclusively administered using the PharmaJet Tropis® NFIS, which was chosen due to the data from numerous published preclinical and clinical studies demonstrating improved immunogenicity when administering DNA-vaccines.1
Chris Cappello, President and CEO, PharmaJet commented, “We are pleased to be partnering with the University of Adelaide as they begin their Omicron COVID-19 booster vaccine trials. Our partners have published 11 studies comparing delivery methods for DNA vaccines that demonstrate increased immunogenicity when using the PharmaJet Systems.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Data on file
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet’s Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to market. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
1-888-900-4321 Option 3